Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Common Equity (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Common Equity for 3 consecutive years, with $42.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 54.45% to $42.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.0 million through Dec 2025, down 54.45% year-over-year, with the annual reading at $42.0 million for FY2025, 54.45% down from the prior year.
  • Common Equity hit $42.0 million in Q4 2025 for Connect Biopharma Holdings, down from $55.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $110.9 million in Q2 2024 to a low of $42.0 million in Q4 2025.
  • Historically, Common Equity has averaged $83.4 million across 3 years, with a median of $92.2 million in 2024.
  • Biggest five-year swings in Common Equity: decreased 9.19% in 2024 and later plummeted 54.45% in 2025.
  • Year by year, Common Equity stood at $101.5 million in 2023, then fell by 9.19% to $92.2 million in 2024, then tumbled by 54.45% to $42.0 million in 2025.
  • Business Quant data shows Common Equity for CNTB at $42.0 million in Q4 2025, $55.4 million in Q3 2025, and $71.3 million in Q2 2025.